• +1-646-491-9876
    • +91-20-67278686

    Search

    Cancer Anorexia-Cachexia Syndrome-Pipeline Review H2 2017

    Cancer Anorexia-Cachexia Syndrome-Pipeline Review H2 2017

    • Report Code ID: RW00011060434
    • Category Life Sciences
    • No. of Pages 93
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

    Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. Cancer anorexia or cachexia often is associated with weakness, fatigue, and a poor quality of life. This symptom of anorexia not only affects the patient but also frequently has an impact on family members, as the patient is no longer able to participate fully in eating as a social activity.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

    Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
    -The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Global Markets Direct Report Coverage
    Cancer Anorexia-Cachexia Syndrome-Overview
    Cancer Anorexia-Cachexia Syndrome-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Cancer Anorexia-Cachexia Syndrome-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Cancer Anorexia-Cachexia Syndrome-Companies Involved in Therapeutics Development
    Abreos Biosciences Inc
    Acacia Pharma Ltd
    Aeterna Zentaris Inc
    Incyte Corp
    Lakewood-Amedex Inc
    Novartis AG
    Paradigm Biopharmaceuticals Ltd
    RaQualia Pharma Inc
    Viking Therapeutics Inc
    Zeria Pharmaceutical Co Ltd
    Cancer Anorexia-Cachexia Syndrome-Drug Profiles
    (formoterol fumarate + megestrol acetate)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    anamorelin hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-380-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVGN-7-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-1889-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DLN-101-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ENERGIF-706-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EXT-400-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Foxo1-nRNA-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HM-03-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IP-1510-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    macimorelin acetate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NEO-1940-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RQ-00433412-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ruxolitinib phosphate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides for Cancer Cachexia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TCMCB-07-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VK-5211-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Z-505-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cancer Anorexia-Cachexia Syndrome-Dormant Projects
    Cancer Anorexia-Cachexia Syndrome-Discontinued Products
    Cancer Anorexia-Cachexia Syndrome-Product Development Milestones
    Featured News & Press Releases
    May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
    Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
    Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer
    Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
    Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL
    Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
    Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
    Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
    Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
    Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
    Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
    Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia
    Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
    Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June
    Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables
    Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Abreos Biosciences Inc, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Acacia Pharma Ltd, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Aeterna Zentaris Inc, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Incyte Corp, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Lakewood-Amedex Inc, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Novartis AG, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by RaQualia Pharma Inc, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Viking Therapeutics Inc, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Dormant Projects, H2 2017
    Cancer Anorexia-Cachexia Syndrome-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Cancer Anorexia-Cachexia Syndrome-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Abreos Biosciences Inc
    Acacia Pharma Ltd
    Aeterna Zentaris Inc
    Incyte Corp
    Lakewood-Amedex Inc
    Novartis AG
    Paradigm Biopharmaceuticals Ltd
    RaQualia Pharma Inc
    Viking Therapeutics Inc
    Zeria Pharmaceutical Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//cancer-anorexia-cachexia-syndrome-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//cancer-anorexia-cachexia-syndrome-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//cancer-anorexia-cachexia-syndrome-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments